Light‐Activated In Situ Vaccine with Enhanced Cytotoxic T Lymphocyte Infiltration and Function for Potent Cancer Immunotherapy
Advanced Science · 2024
DOI: 10.1002/advs.202403158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Xian An und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA & Department of Oncology, Chinese PLA General Hospital, Beijing, 100193, P. R. China. Hauptthemen laut MEDLINE: T-Lymphocytes, Cytotoxic, Cancer Vaccines, Immunotherapy, Tumor Microenvironment. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Innovation Capability Support Program of Shaanxi.
Abstract (Originalsprache)
In situ cancer vaccination is an attractive strategy that stimulates protective antitumor immunity. Cytotoxic T lymphocytes (CTLs) are major mediators of the adaptive immune defenses, with critical roles in antitumor immune response and establishing immune memory, and are consequently extremely important for in situ vaccines to generate systemic and lasting antitumor efficacy. However, the dense extracellular matrix and hypoxia in solid tumors severely impede the infiltration and function of CTLs, ultimately compromising the efficacy of in situ cancer vaccines. To address this issue, a robust in situ cancer vaccine, Au@MnO 2 nanoparticles (AMOPs), based on a gold nanoparticle core coated with a manganese dioxide shell is developed. The AMOPs modulated the unfavorable tumor microenvironment (TME) to restore CTLs infiltration and function and efficiently induced immunogenic cell death. The Mn 2+ ‐mediated stimulator of the interferon genes pathway can be activated to further augment the therapeutic efficacy of the AMOPs. Thus, the AMOPs vaccine successfully elicited long‐lasting antitumor immunity to considerably inhibit primary, recurrent, and metastatic tumors. This study not only highlights the importance of revitalizing CTLs efficacy against solid tumors but also makes progress toward overcoming TME barriers for sustained antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School of Chinese PLA & Department of Oncology, Chinese PLA General Hospital, Beijing, 100193, P. R. China.
- Lab of Molecular Imaging and Translational Medicine (MITM), Engineering Research Center of Molecular & Neuro-imaging, Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 7101…
- Department of Emergency, The Fifth Medical Center of PLA General Hospital, Beijing, 100193, P. R. China.
- School of Medicine, Nankai University, Tianjin, 300071, P. R. China.
ORCID-Profile: Zhongliang Wang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Innovation Capability Support Program of Shaanxi
- Shaanxi Fundamental Science Research Project for Chemistry and Biology
- Key Research and Development Program of Shaanxi
- Open Project Program of the State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers
Zitieren
APA
An, X., Chen, Z., Luo, Y., Yang, P., Yang, Z., Ji, T., Chi, Y., Wang, S., Zhang, R., Wang, Z., & Li, J. (2024). Light‐Activated In Situ Vaccine with Enhanced Cytotoxic T Lymphocyte Infiltration and Function for Potent Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202403158
Vancouver
An X, Chen Z, Luo Y, Yang P, Yang Z, Ji T, et al. Light‐Activated In Situ Vaccine with Enhanced Cytotoxic T Lymphocyte Infiltration and Function for Potent Cancer Immunotherapy. Advanced Science. 2024. doi:10.1002/advs.202403158
BibTeX
@article{An2024,
author = {An, Xian and Chen, Zhuang and Luo, Yi and Yang, Peng and Yang, Zuo and Ji, Tiannan and Chi, Yajing and Wang, Shuyuan and Zhang, Ruili and Wang, Zhongliang and Li, Jianxiong},
title = {Light‐Activated In Situ Vaccine with Enhanced Cytotoxic T Lymphocyte Infiltration and Function for Potent Cancer Immunotherapy},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202403158}
}
EUVIMED